0001562180-20-003096.txt : 20200422
0001562180-20-003096.hdr.sgml : 20200422
20200422201727
ACCESSION NUMBER: 0001562180-20-003096
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200420
FILED AS OF DATE: 20200422
DATE AS OF CHANGE: 20200422
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Valentine Karen
CENTRAL INDEX KEY: 0001437152
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38584
FILM NUMBER: 20808953
MAIL ADDRESS:
STREET 1: C/O ANTIGENICS INC.
STREET 2: 3 FORBES RD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CONSTELLATION PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001434418
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-714-0555
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2020-04-20
false
0001434418
CONSTELLATION PHARMACEUTICALS INC
CNST
0001437152
Valentine Karen
C/O CONSTELLATION PHARMACEUTICALS, INC.
215 FIRST STREET, SUITE 200
CAMBRIDGE
MA
02142
false
true
false
false
See Remarks
Common Stock
2020-04-20
4
M
false
789.00
11.50
A
789.00
D
Common Stock
2020-04-20
4
S
false
789.00
33.6503
D
0.00
D
Stock Option (Right to Buy)
11.50
2020-04-20
4
M
false
789.00
0.00
D
2028-07-18
Common Stock
789.00
114385.00
D
These trades were made pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $35.13 to $35.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 16, 2022.
/s/ Emma Reeve, as Attorney-in-Fact for Karen Valentine
2020-04-22